New drug aims to shield cancer patients from chemo side effects
NCT ID NCT07473128
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests if trilaciclib can protect bone marrow in people with limited-stage small cell lung cancer receiving chemotherapy. About 120 participants will get either trilaciclib or a placebo. The goal is to reduce severe low white blood cell counts and other complications from chemo.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LIMITED-STAGE SMALL-CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Pharmacosmos Investigational Site
RECRUITINGOakland, California, 48073, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Gut check: could sauerkraut and fiber help fight cancer?
- New drug combo aims to fight lung cancer after chemoradiation
- New drug combo aims to keep lung cancer at bay longer
- Gut bacteria boost? new combo therapy aims to improve lung cancer outcomes
- New drug cocktail aims to control aggressive lung cancer
- New immunotherapy combo shows promise for tough lung cancer